Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MKKGY Merck KGaA	$26.67 -0.4%	$26.19	$23.73 ▼ $31.00	$17.23B	0.97	120,590 shs	93,539 shs
TAK Takeda Pharmaceutical	$16.49 -0.9%	$17.82	$12.99 ▼ $18.90	$52.46B	-0.06	2.97 million shs	4.36 million shs
UCBJY UCB	$138.20 +1.9%	$147.64	$84.94 ▼ $168.76	$52.25B	0.45	39,470 shs	22,736 shs
ZTS Zoetis	$82.80 -5.2%	$118.49	$81.10 ▼ $172.23	$34.83B	0.87	4.61 million shs	17.18 million shs

The 7 Hottest IPOs On Wall Street’s 2026 Watchlist

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MKKGY Merck KGaA	+0.06%	+3.40%	+6.31%	-7.53%	-2.72%
TAK Takeda Pharmaceutical	-0.54%	-0.54%	-9.13%	-7.13%	+10.33%
UCBJY UCB	-2.02%	+1.05%	-12.11%	-12.46%	+52.77%
ZTS Zoetis	-22.02%	-24.42%	-25.57%	-31.72%	-44.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MKKGY Merck KGaA	$26.67 -0.4%	$26.19	$23.73 ▼ $31.00	$17.23B	0.97	120,590 shs	93,539 shs
TAK Takeda Pharmaceutical	$16.49 -0.9%	$17.82	$12.99 ▼ $18.90	$52.46B	-0.06	2.97 million shs	4.36 million shs
UCBJY UCB	$138.20 +1.9%	$147.64	$84.94 ▼ $168.76	$52.25B	0.45	39,470 shs	22,736 shs
ZTS Zoetis	$82.80 -5.2%	$118.49	$81.10 ▼ $172.23	$34.83B	0.87	4.61 million shs	17.18 million shs

The 7 Hottest IPOs On Wall Street’s 2026 Watchlist

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MKKGY Merck KGaA	+0.06%	+3.40%	+6.31%	-7.53%	-2.72%
TAK Takeda Pharmaceutical	-0.54%	-0.54%	-9.13%	-7.13%	+10.33%
UCBJY UCB	-2.02%	+1.05%	-12.11%	-12.46%	+52.77%
ZTS Zoetis	-22.02%	-24.42%	-25.57%	-31.72%	-44.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MKKGY Merck KGaA	2.00	Hold	N/A	N/A
TAK Takeda Pharmaceutical	2.50	Moderate Buy	N/A	N/A
UCBJY UCB	4.00	Strong Buy	N/A	N/A
ZTS Zoetis	2.40	Hold	$141.25	70.59% Upside

Current Analyst Ratings Breakdown

Latest MKKGY, TAK, UCBJY, and ZTS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/8/2026	ZTS Zoetis	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Neutral	$130.00 ➝ $99.00
5/8/2026	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$105.00
5/8/2026	ZTS Zoetis	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$190.00 ➝ $130.00
4/29/2026	TAK Takeda Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
4/28/2026	ZTS Zoetis	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$136.00 ➝ $130.00
4/15/2026	ZTS Zoetis	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$145.00
4/15/2026	ZTS Zoetis	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$145.00
4/14/2026	UCBJY UCB	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/8/2026	TAK Takeda Pharmaceutical	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
3/27/2026	ZTS Zoetis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
3/19/2026	MKKGY Merck KGaA	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold

(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MKKGY Merck KGaA	$23.87B	0.72	$8.58 per share	3.11	$50.18 per share	0.53
TAK Takeda Pharmaceutical	$4.46T	0.01	$3.13 per share	5.26	$14.39 per share	1.15
UCBJY UCB	$8.76B	5.97	N/A	N/A	N/A	∞
ZTS Zoetis	$9.51B	3.66	$5.63 per share	14.70	$7.56 per share	10.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MKKGY Merck KGaA	$2.95B	$2.25	11.85	13.27	2.42	12.31%	9.03%	5.25%	5/13/2026 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.24	68.69	12.98	N/A	2.58%	10.60%	5.21%	5/13/2026 (Estimated)
UCBJY UCB	$1.76B	N/A	N/A	19.36	1.31	N/A	N/A	N/A	7/26/2026 (Estimated)
ZTS Zoetis	$2.67B	$6.03	13.75	10.94	1.71	28.24%	62.02%	19.24%	N/A

Latest MKKGY, TAK, UCBJY, and ZTS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2026	N/A	MKKGY Merck KGaA	$0.45	N/A	N/A	N/A	$5.94 billion	N/A
5/13/2026	Q4 2026	TAK Takeda Pharmaceutical	-$0.0754	N/A	N/A	N/A	$7.17 billion	N/A
5/7/2026	Q1 2026	ZTS Zoetis	$1.60	$1.53	-$0.07	$1.42	$2.30 billion	$2.26 billion
3/5/2026	Q4 2025	MKKGY Merck KGaA	$0.47	$0.28	-$0.19	$0.28	$6.20 billion	$6.11 billion
2/12/2026	Q4 2025	ZTS Zoetis	$1.40	$1.48	+$0.08	$1.37	$2.36 billion	$2.39 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MKKGY Merck KGaA	$0.34	1.27%	N/A	15.11%	N/A
TAK Takeda Pharmaceutical	$0.50	3.03%	-2.41%	208.33%	N/A
UCBJY UCB	$0.52	0.38%	N/A	N/A	N/A
ZTS Zoetis	$2.12	2.56%	+20.11%	35.16%	14 Years

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MKKGY Merck KGaA	0.37	1.46	0.96
TAK Takeda Pharmaceutical	0.56	1.19	0.65
UCBJY UCB	0.20	1.38	1.04
ZTS Zoetis	2.71	3.03	1.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MKKGY Merck KGaA	0.10%
TAK Takeda Pharmaceutical	9.17%
UCBJY UCB	N/A
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
MKKGY Merck KGaA	N/A
TAK Takeda Pharmaceutical	0.04%
UCBJY UCB	N/A
ZTS Zoetis	0.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MKKGY Merck KGaA	62,461	646.21 million	N/A	Not Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable
UCBJY UCB	10,117	378.04 million	N/A	Not Optionable
ZTS Zoetis	14,500	420.64 million	419.72 million	Optionable

MKKGY, TAK, UCBJY, and ZTS Headlines

Recent News About These Companies

Zoetis (NYSE:ZTS) Price Target Cut to $130.00 by Analysts at JPMorgan Chase & Co.

3 hours ago | marketbeat.com

Zoetis Inc. $ZTS Holdings Lowered by Premier Fund Managers Ltd

May 8 at 6:42 AM | marketbeat.com

Zoetis Inc. $ZTS Shares Sold by Sumitomo Mitsui DS Asset Management Company Ltd

May 8 at 6:02 AM | marketbeat.com

Zoetis Inc. $ZTS Shares Sold by Crestwood Advisors Group LLC

May 8 at 4:31 AM | marketbeat.com

Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Zoetis Inc.

May 7 at 9:56 PM | prnewswire.com

Zoetis Earnings Call Balances Strength And Strain

May 7 at 8:30 PM | tipranks.com

Promising Medical Stocks To Research - May 7th

May 7 at 3:46 PM | marketbeat.com

Why Zoetis Shares Plummeted Today

May 7 at 3:10 PM | fool.com

Zoetis Inc. (ZTS) Q1 2026 Earnings Call Transcript

May 7 at 3:05 PM | seekingalpha.com

US Pet Care Demand Is Weak - Zoetis Cuts Outlook

May 7 at 1:50 PM | benzinga.com

Zoetis Stock (ZTS) Opinions on Q1 Earnings Miss and Guidance Cut

May 7 at 1:50 PM | quiverquant.comQ

Zoetis Q1 Earnings Lag Estimates, 2026 View Cut, Stock Down

May 7 at 1:50 PM | zacks.com

US Pet Care Demand Is Weak - Zoetis Cuts Outlook

May 7 at 1:33 PM | benzinga.com

Zoetis (ZTS) Stock Plummets 20% Following Disappointing Q1 Results and Guidance Cut

May 7 at 12:31 PM | blockonomi.com

Zoetis Is Today's Worst S&P 500 Stock. Here's Why.

May 7 at 12:03 PM | barrons.com

Zoetis (ZTS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

May 7 at 10:31 AM | zacks.com

Zoetis (NYSE:ZTS) Shares Gap Down After Earnings Miss

May 7 at 10:19 AM | marketbeat.com

Zoetis (ZTS) Misses Q1 Earnings and Revenue Estimates

May 7 at 9:56 AM | zacks.com

Zoetis Inc. 2026 Q1 - Results - Earnings Call Presentation

May 7 at 9:01 AM | seekingalpha.com

Zoetis (NYSE:ZTS) Updates FY 2026 Earnings Guidance

May 7 at 8:10 AM | marketbeat.com

K.J. Harrison & Partners Inc Grows Position in Zoetis Inc. $ZTS

May 7 at 7:19 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MKKGY, TAK, UCBJY, and ZTS Company Descriptions

Merck KGaA OTCMKTS:MKKGY

$26.67 -0.11 (-0.41%)

As of 03:57 PM Eastern

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

Takeda Pharmaceutical NYSE:TAK

$16.48 -0.16 (-0.93%)

Closing price 03:58 PM Eastern

Extended Trading

$16.46 -0.02 (-0.12%)

As of 04:10 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

UCB OTCMKTS:UCBJY

$138.20 +2.60 (+1.92%)

As of 03:57 PM Eastern

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Zoetis NYSE:ZTS

$82.80 -4.51 (-5.17%)

Closing price 03:59 PM Eastern

Extended Trading

$82.81 +0.01 (+0.01%)

As of 06:26 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MKKGY, TAK, UCBJY, and ZTS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MKKGY, TAK, UCBJY, and ZTS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MKKGY, TAK, UCBJY, and ZTS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MKKGY, TAK, UCBJY, and ZTS Company Descriptions

Merck KGaA OTCMKTS:MKKGY

Takeda Pharmaceutical NYSE:TAK

UCB OTCMKTS:UCBJY

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MKKGY, TAK, UCBJY, and ZTS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MKKGY, TAK, UCBJY, and ZTS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MKKGY, TAK, UCBJY, and ZTS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MKKGY, TAK, UCBJY, and ZTS Company Descriptions

Merck KGaA OTCMKTS:MKKGY

Takeda Pharmaceutical NYSE:TAK

UCB OTCMKTS:UCBJY

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools